Adamas Pharma (ADMS) Misses Q4 EPS by 13c

Adamas Pharma (NASDAQ: ADMS) reported Q4 EPS of ($0.64), $0.13 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $21 million versus the consensus estimate of $20.96 million.

As of December 31, 2020, Adamas had $83.4 million of cash, cash equivalents and available-for-sale securities. Subsequent to December 31, 2020, and through February 16, 2021, Adamas raised net proceeds of approximately $7.2 million under an at-the-market offering.

“We are excited with the opportunities ahead of us, including the continued growth of GOCOVRI which is now the first and only medication approved to treat both OFF and dyskinesia motor complications in Parkinson’s disease,” said Neil F. McFarlane, Chief Executive Officer. “Bolstered by the launch of a second indication, GOCOVRI is now approved to treat approximately 400,000 to 500,000 Parkinson’s patients. The significant progress made across the business in 2020 fueled positive momentum into 2021, and we are leveraging this as we continue to successfully execute our long-term growth strategy.”

For earnings history and earnings-related data on Adamas Pharma (ADMS) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Steel Dynamics (STLD) Tops Q1 EPS by 16c
• Chubb Corp. (CB) Tops Q1 EPS by 10c